Decreased Expression of C10orf10 and Its Prognostic Significance in Human Breast Cancer

Deng, Junjiang; Dong, Yan; Li, Chong; Zuo, Wenwei; Ma, Gang; Xu, Chunfang; Li, Jianjun

doi:10.1371/journal.pone.0099730

Cited by 6 publications

(4 citation statements)

References 28 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, we also identified IGF2 as a differentially expressed gene between tumor and non-tumor ovarian tissues (19), and we confirmed its expression in normal, corresponding non-cancerous and cancerous ovarian tissues by reverse transcription-polymerase chain reaction (RT-PCR), real-time quantitative PCR (RT-qPCR), western blotting and IHC. Furthermore, the prognostic significance of IGF2 expression was analyzed in human ovarian cancers.…”

Section: Introductionsupporting

confidence: 72%

High IGF2 expression is associated with poor clinical outcome in human ovarian cancer

Dong

Han

et al. 2015

Oncology Reports

Self Cite

View full text Add to dashboard Cite

Ovarian cancer is one of the most common types of cancer in females and is the leading cause of death among gynaecological cancers in women worldwide. In the present study, we identified insulin-like growth factor 2 (IGF2) as a differentially expressed gene between cancerous and non-cancerous ovarian tissues. IGF2 was frequently increased in the human ovarian cancers when compared to the frequency in the non-cancerous ovarian tissues both at the mRNA (30/35) and protein level (61/72). The mean level of IGF2 in the tumor tissues was markedly higher than that in the non-cancerous tissues (nearly 3-fold change) (P=0.000). There was a significant correlation of IGF2 expression with histological grade (P=0.047). Kaplan-Meier analysis indicated that the ovarian cancer patients with high IGF2 expression showed a poorer prognosis both in regards to overall survival (OS) and progression-free survival (PFS) (n=1,648, P=0.000). Further analysis revealed that high expression of IGF2 was an unfavorable factor for the prognosis of the ovarian cancer patients at clinical stage I + II, stage III, histological grade 2, grade 3 or those treated with chemotherapy containing platin and Taxol. Our data provide evidence that IGF2 expression is frequently increased in ovarian cancer tissues, and high expression of IGF2 may be a significant prognostic factor for poor survival in ovarian cancer patients.

show abstract

Section: Introductionsupporting

confidence: 72%

High IGF2 expression is associated with poor clinical outcome in human ovarian cancer

Dong

Han

et al. 2015

Oncology Reports

Self Cite

View full text Add to dashboard Cite

show abstract

“…C10orf10 plays a role in cell cycle regulation and DNA repair 19 . Lower expression levels correlate with worse BC outcomes 20 and higher levels are linked to glioma proliferation 21 . These ndings suggest C10orf10's relevance not only to gliomas but also to the prognosis of CD-related BC.…”

Section: Discussionmentioning

confidence: 99%

Unraveling the Causal Links and Novel Molecular Classification of Crohn’s Disease in Breast Cancer: A Two-Sample Mendelian Randomization and Transcriptome Analysis with Prognostic Modeling

Yu,

Huang

et al. 2023

Preprint

View full text Add to dashboard Cite

Background Crohn’s disease (CD), a prominent manifestation of chronic gastrointestinal inflammation, and breast cancer (BC), seemingly disparate in the medical domain, exhibit a shared characteristic. This convergence arises from their involvement in chronic inflammation and immune responses, an aspect that has progressively captivated the attention of investigators but remain controversy. Methods We used two-sample Mendelian Randomization (MR) and transcriptomics to explore the relationship between CD and BC. MR assessed causality of CD on different BC subtypes and reverse causality of BC on CD. We identified CD-related differentially expressed genes and their prognostic impact on BC, and developed a new molecular BC classification based on these key genes. Results MR revealed a causal link between CD and increased BC risk, especially in estrogen receptor-positive (ER+) patients, but not in ER-negative (ER-) cases. BC showed no causal effect on CD. Transcriptomics pinpointed genes like B4GALNT2 and FGF19 that affected BC prognosis in CD patients. A nomogram based on these genes predicted BC outcomes with high accuracy. BC patients were reclassified into three prognostically distinct subtypes using these genes. Conclusions CD is a risk factor for ER + BC but not for ER- BC. BC does not causally affect CD. Our prognostic model and new BC molecular classifications offer insights for personalized treatment strategies.

show abstract

“…DEPP was first identified as a protein related to progesterone in endometrial stromal cells [27,28]. Accumulating evidence has shown that DEPP is positively linked with breast cancer and has a connection with energy deprivation and ionizing radiation [29][30][31]. Specifically, levels of DEPP are elevated in response to starvation and oxidative stress, which in turn promoted reactive oxygen species (ROS) accumulation, resulting in mitochondrial dysfunction and apoptosis [32].…”

Section: Discussionmentioning

confidence: 99%

PLCL1 suppresses tumour progression by regulating AMPK/mTOR-mediated autophagy in renal cell carcinoma

Pan,

Huang,

Song

et al. 2023

Aging

View full text Add to dashboard Cite

Autophagy has been increasingly recognized as a critical regulatory mechanism in the maintenance of cellular homeostasis. A previous study showed that phospholipase C-like protein 1 (PLCL1) is associated with lipid metabolism in renal cell carcinoma (RCC). However, it is unclear whether PLCL1 regulates autophagy, thereby influencing the progression of RCC. Bioinformatics analysis of five microarray datasets revealed that expression of PLCL1 is decreased in tumours and is positively correlated with prognosis in RCC patients. Three independent public datasets, clinical RCC tissues and RCC cell lines, were validated using real-time qPCR, western blotting and immunohistochemistry. Using wound healing and transwell assays, we observed that elevated PLCL1 levels decreased the migratory distance and the invasive number of 786-O and ACHN cells, but PLCL1 knockdown reversed these changes in 769P cell lines compared to those in controls. The results of flow cytometry analysis indicated that PLCL1 promotes apoptosis. Moreover, transcriptional analysis based on stable overexpression of PLCL1 in 786-O cells revealed that PLCL1 is related to autophagy, and western blotting and autophagic experimental results further verified these findings. Mechanistic investigations confirmed that PLCL1 activates the AMPK/mTOR pathway and interacts with decidual protein induced by progesterone (DEPP). Collectively, our data suggest that PLCL1 functions as a suppressor of RCC progression by activating the AMPK/mTOR pathway, interacting with DEPP, initiating autophagy and inducing apoptosis. PLCL1 may be a promising therapeutic target for the diagnosis and treatment of ccRCC patients.

show abstract

Decreased Expression of C10orf10 and Its Prognostic Significance in Human Breast Cancer

Cited by 6 publications

References 28 publications

High IGF2 expression is associated with poor clinical outcome in human ovarian cancer

High IGF2 expression is associated with poor clinical outcome in human ovarian cancer

Unraveling the Causal Links and Novel Molecular Classification of Crohn’s Disease in Breast Cancer: A Two-Sample Mendelian Randomization and Transcriptome Analysis with Prognostic Modeling

PLCL1 suppresses tumour progression by regulating AMPK/mTOR-mediated autophagy in renal cell carcinoma

Contact Info

Product

Resources

About